Together We Succeed

DotsP1

Ophidion CNS Carrier Technology

Ophidion’s CNS Carrier Technology (or OCCT) is available for partnering. We look forward to enabling third parties to enhance the penetration of their pipeline or marketed products (life cycle management) to the brain. The OCCT can be coupled with small molecules, including peptides, gene silencing therapeutics like , siRNAs and ASOs, and other macromolecules (e.g. antibodies, oligonucleotides, etc.).

Ophidion’s CNS Pipeline

Ophidion is looking for co-development partners for the Huntington’s (OCCT-HTT siRNA) and cognition (OCCT-lynx1 siRNA) programs in the USA and for out-licensing the rights for these two programs outside the USA, including Europe, China, and Japan. In addition, Ophidion is looking to develop other pipeline products to preclinical proof of concept before out-licensing them to third parties.

Ophidion’s CNS Pipeline

Ophidion is seeking to out-license the Analgesia (OCCT-neurotensin) program as well as the anxiety program on a worldwide basis. In addition, Ophidion is looking for codevelopment partners for the Huntington’s (OCCT-HTT siRNA) and cognition (OCCT-lynx1 siRNA) programs in the USA and for out-licensing the rights for these two programs outside the USA, including Europe, China, and Japan.

Partnering Opportunities

Ophidion’s CNS Carrier Technology (OCCT)

  • Available for partnering with third parties’ pipeline or marketed products

Huntington’s Disease
(OCCT-HTT siRNA)

  • Available for partnering in ex-U.S. regions (Europe, China, and Japan)

  • For the U.S.: looking for codevelopment partners

Cognition (OCCT-lynx1 siRNA)

  • Available for partnering in ex-U.S. regions (Europe, China, and Japan)

  • For the U.S.: looking for codevelopment partners

Other Pipeline Products

  • Parkinson’s Disease

  • Progressive Supranuclear Palsy

  • Alzheimer’s Disease

  • Amyotrophic Lateral Sclerosis (ALS)

  • ALS / Frontotemporal Dementia

  • Glioblastoma multiforme

Available for out-licensing on a worldwide basis

Contact

Interested in partnering, contact Yacoub Habib, CEO.
Tel: (973) 687-2165
Email: [email protected]